未登录

G

Guanzhang Li

capital medical university

H指数:32

被引数:4,785

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features

MET融合与剪接变异在胶质瘤中的研究：整合临床、病理及生存特征的全面分析

Journal of Pathology Clinical Research

IF3.7

2026-03-300

OAAI

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

CD44/CD133双靶向IL7Rα装甲CAR-T细胞在胶质母细胞瘤中的开发及其强大的抗肿瘤功效

IF10.1

2025-04-010

PRE

Targeting the lysine lactylome for the treatment of glioma

CANCER BIOLOGY & MEDICINE

IF8.4

2024-12-300

OAAI

PTBP1-mediated repression of neuron-specific CDC42 splicing constitutes a genomic alteration-independent, developmentally conserved vulnerability in IDH-wildtype glioblastoma

FUNCTIONAL & INTEGRATIVE GENOMICS

IF3.1

2024-08-091

PRE

Multi-omics and pharmacological characterization of patient-derived glioma cell lines

NATURE COMMUNICATIONS

IF15.7

2024-08-080

OAAI

Poliovirus receptor-based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2023-11-071

OAAI

MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant

BRAIN PATHOLOGY

IF6.2

2023-08-021

OAAI

Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA (vol 19, pg 1460, 2022)

CANCER BIOLOGY & MEDICINE

IF8.4

2023-07-241

OAAI

Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

IF3.9

2023-04-182

OAAI

Temporal and spatial stability of the EM/PM molecular subtypes in adult diffuse glioma

FRONTIERS OF MEDICINE

IF3.5

2023-01-162

PRE

TREM2 is associated with tumor immunity and implies poor prognosis in glioma

TREM2与肿瘤免疫相关，提示胶质瘤预后不良

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-01-1117

OAAI

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes

人类少突胶质细胞瘤的免疫学特征定义了两种不同的分子亚型

IF10.8

2023-01-019

OAAI

Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA

CANCER BIOLOGY & MEDICINE

IF8.4

2022-11-0138

OAAI

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas

CANCER BIOLOGY & MEDICINE

IF8.4

2022-11-0110

OAAI

A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma

CNS NEUROSCIENCE & THERAPEUTICS

IF5

2022-08-1918

OAAI

Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology

BIOTECHNOLOGY JOURNAL

IF3.1

2022-04-031

OAAI

An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas

IF11.7

2022-02-06136

OAAI

Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells

FRONTIERS IN BIOSCIENCE-LANDMARK

IF3.1

2022-01-182

OA

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-12-087

OAAI

Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas

高剂量放疗与新诊断低级别胶质瘤患者生存率改善的关系

IF5.1

2021-11-1513

OAAI